Programmed Death Ligand-1 and Tumor Mutation Burden Testing of Patients With Lung Cancer for Selection of Immune Checkpoint Inhibitor Therapies: Guideline From the College of American Pathologists, Association for Molecular Pathology, International Association for the Study of Lung Cancer, Pulmonary Pathology Society, and LUNGevity Foundation.
Lynette M ShollMark AwadUpal Basu RoyMary Beth BeasleyRichard Walter CartunDavid M HwangGregory KalemkerianFernando Lopez-RiosMari Mino-KenudsonAjit PaintalKearin ReidLauren RitterhouseLesley A SouterPaul E SwansonChristina B VenturaLarissa V FurtadoPublished in: Archives of pathology & laboratory medicine (2024)
This guideline summarizes the current understanding and hurdles associated with the use of PD-L1 expression and TMB testing for immune checkpoint inhibitor therapy selection in patients with advanced non-small cell lung cancer and presents evidence-based recommendations for PD-L1 and TMB testing in the clinical setting.